Contemporary pharmacological management of anemia associated with chronic kidney disease.
INTRODUCTION Iron supplementation, erythropoiesis-stimulating agents (ESAs), and hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are currently the main therapeutic options for anemia associated with chronic kidney disease (CKD). In 2026, KDIGO published an updated clinical practice guideline for anemi...